Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA FE 1 20 versus HAILEY 24 FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA FE 1 20 versus HAILEY 24 FE.
AUROVELA FE 1/20 vs HAILEY 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. Inhibits ovulation by suppressing gonadotropin release (FSH, LH). Increases viscosity of cervical mucus, reducing sperm penetration. Alters endometrial lining to reduce implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol and norethindrone; inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus, and alters endometrial receptivity.
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by one iron tablet (75 mg ferrous fumarate) orally once daily for 7 days.
One tablet orally once daily for 24 weeks. Each tablet contains norethindrone 0.8 mg and ethinyl estradiol 0.02 mg. After 24 weeks, take one inactive (ferrous fumarate) tablet daily for 4 weeks. Total cycle: 28 tablets.
None Documented
None Documented
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours (with interindividual variability).
Ethinyl estradiol has a terminal half-life of approximately 13-27 hours (mean 18.5 hours). Norethindrone has a terminal half-life of approximately 8-12 hours. The half-life supports once-daily dosing.
Renal: ~50-60% as metabolites; fecal: ~40-50% as metabolites; biliary excretion contributes to fecal elimination.
Ethinyl estradiol is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates. Norethindrone is excreted in urine (30-50%) and feces (20-30%) as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive